Physician profile
Duncan E Darnell
NPI 1003809997
$5,813.24
in general payments reported to CMS, 2019-2025
20 companies · $1,682 in 2025
The $1,682 reported for 2025 was more than what 92% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $651 · 2020: $17.39 · 2021: $465 · 2022: $835 · 2023: $955 · 2024: $1,208 · 2025: $1,682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,844.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $873.11 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $792.28 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $720.84 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $570.33 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $462.79 | 2019-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $424.09 | 2019-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $329.98 | 2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $281.12 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $274.26 | 2021-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $224.28 | 2022-2025 | Uzedy, Austedo Xr, Austedo |
| Corium, LLC | $216.20 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $199.54 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $112.91 | 2024-2025 | Fanapt |
| Ironshore Pharmaceuticals INC. | $98.54 | 2019-2022 | |
| Abbvie INC. | $53.80 | 2021-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $53.37 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $51.46 | 2022-2024 | Quviviq |
| Uswm, LLC | $37.28 | 2022 | |
| Sun Pharmaceutical Industries INC. | $18.68 | 2021 | |
| Shire North American Group INC | $18.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Duncan Darnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.